Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study-Reference-Cited by-同舟云学术

Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study

Published:2023-05-31 Issue:3 Volume:76 Page:174-182
ISSN:1344-6304
Container-title:Japanese Journal of Infectious Diseases
language:en
Short-container-title:Jpn J Infect Dis

Author:

Matsuoka Osamu¹,Ujiie Mugen²,Kikuchi Hitoshi³,Otake Sachiko¹,Chansinghakul Danaya⁴,Inoue Takahiro⁵,Varghese Kucku⁶,Sirisuphmitr Nuchra⁷,Hashiguchi Tomoyuki⁸,Zambrano Betzana⁹,Nakama Takahiro¹⁰,Frago Carina¹¹,Jordanov Emilia¹²,Dhingra Mandeep Singh¹²

Affiliation:

1. Medical Corporation Heishinkai ToCROM Clinic, Japan

2. Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan

3. Meitetsu Hospital, Japan

4. Global Clinical Development Strategy, Sanofi, Thailand

5. Clinical Sciences & Operations, R & D, Sanofi K. K., Japan

6. Global Clinical Immunology, Sanofi, USA

7. Clinical Study Management, Sanofi, Thailand

8. NV Portfolio Strategy & Execution, Sanofi, Japan

9. Global Clinical Development Strategy, Sanofi, Uruguay

10. Global Clinical Development Strategy, Sanofi, Japan

11. Global Clinical Development Strategy, Sanofi, Singapore